Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024
Cooley M&A
JANUARY 23, 2024
Looming patent cliffs By 2030, more than 190 drugs will lose patent exclusivity , including 69 blockbuster drugs, putting at risk $236 billion in sales. Many buyers have adjusted their valuation expectations across the market accordingly, while the adoption of a “new normal” worldview catches hold more gradually on the sell side.
52 
Let's personalize your content